Jean-Nicolas Cornu, Professor of Urology at CHU de Rouen, shared on LinkedIn:
“Movember day 13!
Major milestone in prostate cancer screening!
And what better timing than Movember?
The American Cancer Society (ACS) has just released its updated 2026 guidelines for the early detection of prostate cancer, published Open Access in CA: A Cancer Journal for Clinicians.
Title: American Cancer Society guideline for the early detection of prostate cancer, 2026
Authors: Richard M. Hoffman, Andrew M. D. Wolf, Ruth D. Etzioni, Kevin C. Oeffinger, Sana Raoof, Louise C. Walter, Charnita Zeigler-Johnson, Timothy R. Church, Christopher K. Jones, Artie L. Shelton, Elena B. Elkin, Carmen E. Guerra, Rebecca B. Perkins, Ya-Chen Tina Shih, Steven J. Skates, Roman Gulati, Hormuzd A. Katki, Tyler B. Kratzer, Deana Manassaram-Baptiste, William L. Dahut, Robert A. Smith
And this is major shift.
For the first time, the ACS now explicitly recommends regular PSA-based screening, moving beyond its previous approach centred primarily on shared decision-making.
- Average-risk men aged 50 – 69: PSA screening every 2 years.
- Higher-risk men, including Black men and those with a strong family history: annual screening starting at age 45.
- Elevated PSA: repeat testing, followed when appropriate by MRI and/or validated biomarkers to guide biopsy decisions.
- Low-risk prostate cancer: active surveillance should be offered as the initial management strategy.
Why does this matter?
Because the evidence has evolved.
Long-term data increasingly support a reduction in prostate cancer mortality and advanced-stage diagnoses through PSA-based screening.
And importantly, our diagnostic and management strategies have also evolved: MRI, risk stratification, more selective biopsies, and active surveillance can help reduce unnecessary investigations and overtreatment.
This is not about screening everyone indiscriminately.
It is about moving towards more structured, risk-adapted, evidence-based early detection, while preserving informed patient choice.
A remarkable milestone in a debate that has shaped urology for decades.”
You can also read:
- American Cancer Society Journals Highlight New Evidence for PSA-Based Prostate Cancer Screening
- New Prostate Cancer Screening Guidelines Recommend Regular PSA Testing
